Applied Clinical Trials
Proving a biosimilar's pharmacokinetic 'equivalence' requires adherence to several unique factors.
Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Articles by Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Latest Updated Articles
Demonstrating Biosimilarity: PK ConsiderationsOctober 1st 2014
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
2
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
3
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
4
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
5